Recalls / Class II
Class IID-1118-2022
Product
Cefazolin for injection USP, and Dextrose Injection, USP, 2 g, 50 mL duplex container, Rx only, MFG: B. Braun Medical Inc., NDC 0264-3105-11
- Brand name
- Cefazolin Sodium
- Generic name
- Cefazolin Sodium
- Active ingredient
- Cefazolin Sodium
- Route
- Intravenous
- NDCs
- 0264-3103, 0264-3105, 0264-3107
- FDA application
- NDA050779
- Affected lot / code info
- McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.
Why it was recalled
cGMP deviations: Temperature abuse
Recalling firm
- Firm
- Mckesson Medical-Surgical Inc. Corporate Office
- Manufacturer
- B. Braun Medical Inc.
- Notification channel
- Letter
- Type
- Voluntary: Firm initiated
- Address
- 9954 Maryland Drive, Deep Run Iii Ste. 4000, Richmond, Virginia 23233
Distribution
- Quantity
- 39 cases
- Distribution pattern
- USA nationwide.
Timeline
- Recall initiated
- 2022-04-13
- FDA classified
- 2022-06-09
- Posted by FDA
- 2022-06-15
- Terminated
- 2023-11-30
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-1118-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.